Biocon aims to become the world’s top insulin supplier within five years, leveraging growing demand as major pharmaceutical ...

Biocon said that its long-standing partner Duopharma Biotech has secured multiple insulin contracts from the Ministry of Health (MoH), Malaysia, valued at over MYR 225 million this year.

Biocon Limited has announced that its long-standing partner, Duopharma Biotech Berhad, through its wholly owned subsidiary ...

India's Biocon eyes the top spot in the $30 billion global insulin market within five years, as pharma giants Novo Nordisk ...

Biocon's Malaysian partner Duopharma Biotech secures insulin supply contracts worth over MYR 225 million from Malaysia's ...

Biocon, currently the third-largest insulin supplier by volume, has invested “big time” in ramping up production capacity, ...

Solid earnings, robust biosimilars growth, and improving margins drive renewed optimism; analysts see double-digit upside ...

Biocon Biologics and Regeneron executed the settlement agreement to dismiss the pending appeal at the United States Court of Appeals for the Federal Circuit (USCAFC) of patent US11084865 ('865 patent) ...

Kiran Mazumdar-Shaw says the company is expanding capacity to meet growing demand while major drugmakers prioritise newer ...

Viatris Inc. , the company formed by the merger of Mylan and Pfizer Inc. unit Upjohn in 2020, said Monday it has reached an agreement to combine its biosimilars portfolio with Biocon Biologics Ltd.

JM Financial anticipates significant shifts in the MSCI India Standard Index. Laurus Labs and Biocon are flagged as ...